Eftansomatropin alfa

Summary

Eftansomatropin alfa (also known as TransCon hGH or lonapegsomatropin in some contexts; brand name Skytrofa is a different prodrug, whereas eftansomatropin alfa is marketed as Ngenla) is a long-acting recombinant human growth hormone Fc fusion protein developed by OPKO Health / Pfizer. It requires once-weekly subcutaneous administration instead of daily injections, improving patient convenience. It is approved for pediatric growth hormone deficiency (pGHD).

Mechanism of Action

Eftansomatropin alfa is a recombinant fusion protein consisting of human growth hormone (hGH) linked to an immunoglobulin Fc fragment (IgG4-Fc), which extends its half-life. It acts as a GH receptor agonist, binding to and activating growth hormone receptors to stimulate IGF-1 production, promote linear growth, and regulate metabolism.

Routes of Administration

Goals & Uses

• Adult growth hormone deficiency (investigational)EndocrinologyLow
• IGF-1 normalizationBiomarker / Surrogate EndpointHigh
• Improved treatment adherence via once-weekly dosingPatient Convenience / AdherenceHigh
• Treatment of pediatric growth hormone deficiency (pGHD)Endocrinology / GrowthHigh

Contraindications

• Active malignancyOncologyHighUse caution or avoid depending on agent and context
• Acute critical illnessCritical CareHigh
• Closed epiphyses (for growth promotion indication)Pediatric / SkeletalModerate
• Diabetic retinopathyOphthalmologyModerate
• Prader-Willi syndrome with severe obesity or respiratory impairmentGenetic SyndromeHigh
• Hypersensitivity to somatropin or excipientsAllergy / ImmunologyHigh

Adverse Effects

• Injection site reactionsLocalCommon
• HeadacheNeurologicCommonPain in the head or upper neck
• Fluid retention / edemaFluid / ElectrolyteUncommon
• Intracranial hypertensionNeurologicalRare
• HypothyroidismEndocrineUncommon
• Elevated IGF-1 levelsEndocrine / LaboratoryCommon

Drug Interactions

• GlucocorticoidsModerate
• Insulin / Oral antidiabeticsModerate
• Thyroid hormone replacementModerate
• CYP450 substrates (e.g., cyclosporine, sex hormones)Low

Population Constraints

• Patients with prior or active malignancyOncologyAbsolute
• PregnancyReproductive SafetyRelative
• AdultsAdult PopulationRelative
• Patients with diabetes mellitusMetabolicRelative
• Children under 3 years of agePediatricRelative

Regulatory Status

• European UnionApprovedApproved: Pediatric growth hormone deficiency (pGHD)EMA approved; marketed as Ngenla in the European Union.
• United StatesApprovedApproved: Pediatric growth hormone deficiency (pGHD) in patients 3 years and olderFDA approved June 2023; marketed as Ngenla by Pfizer/OPKO Health.
• United KingdomApprovedApproved: Pediatric growth hormone deficiency (pGHD)MHRA approved following EMA decision; available as Ngenla.

Approved by the FDA in June 2023 for pediatric patients 3 years and older with growth hormone deficiency. Also approved by the EMA. Developed by OPKO Health in partnership with Pfizer; marketed under the brand name Ngenla.

Evidence & Sources

No sources recorded yet.